RecruitingPhase 2NCT07502508
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy
Sponsor
Biomea Fusion Inc.
Enrollment
60 participants
Start Date
Apr 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria8
- Males or females, age ≥18 years and ≤70 years
- Have been diagnosed with T2D
- Taking Ozempic (semaglutide injection) and have been treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with a stable dose of all medications for at least 3 months prior to screening
- Participants taking metformin must be on a minimum stable dose of ≥500 mg/day
- Participants taking Ozempic must be on a minimum stable dose of ≥0.5 mg/week
- Have HbA1c ≥7.5 and ≤9.5%
- Have a BMI 25 to 40 kg/m2
- Female participants of childbearing potential must have a negative pregnancy test, must be non-lactating and must be willing to have additional pregnancy tests during the study.7. Willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.
Exclusion Criteria6
- Have type 1 diabetes mellitus or a secondary form of diabetes
- Have a history of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to screening
- Have a history of severe hypoglycemia (defined by the occurrence of hypoglycemia symptoms requiring the assistance of another person for recovery) in the 6 months prior to screening or a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms as judged by the investigator
- Have personal or family history (first-degree relative) of MEN1 or MEN2 or medullary thyroid carcinoma
- Use of GLP-1 RA other than Ozempic (semaglutide injection), dual GIP/GLP-1 RA, sulfonylureas, meglitinides, thiazolidinediones, alpha glucosidase inhibitor, DPP4I, bile acid sequestrants, dopamaine-2 agonists, amylin, or insulin in the 3 months prior to screening
- Have FPG ≥240 mg/dL
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGicovamenib 100 mg
icovamenib 100 mg
DRUGPlacebo
Matching placebo
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07502508
Related Trials
Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification
NCT057667352 locations
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
NCT0750249515 locations
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
NCT060031531 location
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
NCT058847751 location
The Food for Health Study
NCT072546891 location